BIOMAT Database Logo BIOMAT Database Logo

[Efficacy of Antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone in Patients Receiving Oxaliplatin-Based Chemotherapy]. 2020

Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Dept. of Pharmacy, Takeda General Hospital.

Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is recommended for moderately emetogenic chemotherapy in several guidelines to prevent chemotherapy-induced nausea and vomiting. There is a lack of information about the efficacy and safety of antiemetic therapy with aprepitant, palonosetron, and dexamethasone in patients treated with oxaliplatin in Japan. We recruited patients with untreated colorectal cancer who underwent oxaliplatin-based chemotherapy. All patients were treated with aprepitant, palonosetron, and dexamethasone. The complete response and complete protection rates were analyzed. A total of 52 patients were enrolled in this clinical trial. The complete response rate overall, and in the acute and delayed phases was 92.3%, 98.1%, and 92.3%, respectively. The complete protection rate overall and in the acute and delayed phases was 73.1%, 86.5%, and 73.1%, respectively. Grade 3-4 non-hematological toxicity did not occur. Antiemetic therapy with aprepitant, palonosetron, and dexamethasone is effective and safe in patients treated with oxaliplatin.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D011812 Quinuclidines A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group. Quinuclidine
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077150 Oxaliplatin An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane, and with an oxalate ligand which is displaced to yield active oxaliplatin derivatives. These derivatives form inter- and intra-strand DNA crosslinks that inhibit DNA replication and transcription. Oxaliplatin is an antineoplastic agent that is often administered with FLUOROURACIL and FOLINIC ACID in the treatment of metastatic COLORECTAL NEOPLASMS. Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1),1,2-Diaminocyclohexane Platinum Oxalate,1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II),ACT 078,ACT-078,Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II),Eloxatin,Eloxatine,L-OHP Cpd,Oxalato-(1,2-cyclohexanediamine)platinum II,Oxaliplatin, (SP-4-2-(1R-trans))-isomer,Oxaliplatin, (SP-4-2-(1S-trans))-isomer,Oxaliplatin, (SP-4-3-(cis))-isomer,Oxaliplatine,Platinum(II)-1,2-cyclohexanediamine Oxalate,1,2 Diaminocyclohexane Platinum Oxalate,ACT078
D000077608 Aprepitant A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. (1-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine,(2R)-(1R)-3,5-bis(Trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine,Emend,L 754,030,L 754030,L-754,030,L-754030,MK 0517,MK 0869,MK 869,MK-0517,MK-0869,MK-869,MK0517,L754,030,L754030,MK0869,MK869
D000077924 Palonosetron Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting. 2-(1-azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one,2-QHBIQO,Aloxi,Palonosetron Hydrochloride,Palonosetron, (3R)-,Palonosetron, (R-(R*,R*))-isomer,Palonosetron, (R-(R*,S*))-isomer,Palonosetron, (S-(R*,S*))-isomer,RS 25233-197,RS 25233-198,RS 25259,RS 25259-197,RS 25259-198,RS-25233-197,RS-25233-198,RS-25259,RS-25259-197,RS-25259-198,RS 25233 197,RS 25233 198,RS 25233197,RS 25233198,RS 25259 197,RS 25259 198,RS 25259197,RS 25259198,RS25233197,RS25233198,RS25259,RS25259197,RS25259198
D000932 Antiemetics Drugs used to prevent NAUSEA or VOMITING. Anti-emetic,Antiemetic,Antiemetic Agent,Antiemetic Drug,Anti-Emetic Effect,Anti-Emetic Effects,Anti-emetics,Antiemetic Agents,Antiemetic Drugs,Antiemetic Effect,Antiemetic Effects,Agent, Antiemetic,Agents, Antiemetic,Anti Emetic Effect,Anti Emetic Effects,Anti emetic,Anti emetics,Drug, Antiemetic,Drugs, Antiemetic,Effect, Anti-Emetic,Effect, Antiemetic,Effects, Anti-Emetic,Effects, Antiemetic
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014839 Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Emesis

Related Publications

Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy.
January 2016, SpringerPlus,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.
August 2012, International journal of clinical practice,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
January 2015, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
February 2016, Biomedical journal,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
August 2014, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy.
April 2018, Clinical breast cancer,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy.
July 1983, Archives of internal medicine,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
December 2012, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
September 2006, The journal of supportive oncology,
Yasuhiro Anzai, and Fumiaki Kawahara, and Aya Kouuchi, and Toshiyasu Watanabe, and Kanako Saito-Inoue, and Yuuko Ishida, and Naomi Saito, and Shinji Kimoto
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
June 2017, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Copied contents to your clipboard!